Overview

Drug-drug Interaction of SHR3680 With Repaglinide and Bupropion

Status:
Recruiting
Trial end date:
2021-05-01
Target enrollment:
Participant gender:
Summary
The DDI study had been designed to investigate the effect of SHR3680 on the pharmacokinetics of Repaglinide and Bupropion
Phase:
Phase 1
Details
Lead Sponsor:
Jiangsu HengRui Medicine Co., Ltd.
Treatments:
Bupropion
Repaglinide